Market Herald logo

Subscribe

Be the first with the news that moves the market

Neurotech’s strategic adviser, Dr. Adrian Attard Trevisan, has been found guilty of misconduct after the Malta Times published an article suggesting he never completed a PhD in neuroscience. 

Dr. Adrian Attard Trevisan has admitted to his wrong-doing, stating he mislead the public and has never completed a PhD in Neuroscience, from the University of College London. But instead, Dr. Attard Trevisan has a completed PhD in Human Physiology from the University of Milan.

As a result, Dr. Adrian Attard Trevisan has resigned, as the director of Neutrotech Limited, in June 2018 and no longer has any involvment with the company and its board or management team.

“Neurotech’s flagship product Mente is the result of much more than the work of one person. Neurotech’s dedicated Mente team has worked for many years to create, refine and improve the device and its therapeutic outcomes – and that work continues today, and into the future,” Neurotech International Limited.

Please find announcement attached: https://hotcopper.com.au/documentembed?id=uOMxKKzFkiWRTLKhOROKAxjvTDYD4Qq0yhKZruNwke92GA%3D%3D

NTI by the numbers
More From The Market Herald
The Market Herald Video

" Cynata Therapeutics (ASX:CYP) to conclude MEND trial following strategic review

Cynata Therapeutics (ASX:CYP) has completed a strategic review of its clinical development pipeline to maximise commercial…
The Market Herald Video

" AVITA Medical (ASX:AVH) reports positive results from soft tissue trial

AVITA Medical (ASX:AVH) reports positive top line results for its RECELL trial in patients with soft-tissue…
Paradigm Biopharmaceuticals (ASX:PAR) - CEO, Marco Polizzi

" Paradigm Biopharmaceuticals (ASX:PAR) enters trading halt amid cap raise

Paradigm Biopharmaceuticals (ASX:PAR) has entered into a trading halt ahead of a capital raise.
HITIQ (ASX:HIQ) - CEO, Mike Vegar

" HITIQ (ASX:HIQ) secures third Australian innovation patent

HITIQ (ASX:HIQ) has secured a third Australian innovation patent related to its virtual reality (VR) concussion…